NASDAQ · SIBN
Healthcare · Medical - Devices
$18.55
Down-$0.01 (-0.05%)
Updated Sep 17, 2026, 12:05 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
SIBN closed at $18.55 after 19 trading sessions, down 6.83% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $18.65 | $18.935 | $18.48 | $18.55 | 429.41K |
| Sep 14, 2026 | $18.54 | $18.80 | $18.295 | $18.70 | 550.96K |
| Sep 11, 2026 | $18.65 | $19.16 | $18.21 | $18.38 | 590.91K |
| Sep 10, 2026 | $18.45 | $18.69 | $17.99 | $18.30 | 686.07K |
| Sep 9, 2026 | $18.82 | $18.875 | $18.33 | $18.41 | 437.52K |
| Sep 8, 2026 | $18.25 | $18.85 | $18.16 | $18.62 | 541.96K |
| Sep 4, 2026 | $18.50 | $18.7466 | $18.195 | $18.50 | 389.53K |
| Sep 3, 2026 | $19.45 | $19.65 | $18.55 | $18.64 | 632.45K |
| Sep 2, 2026 | $18.92 | $19.715 | $18.92 | $19.16 | 786.85K |
| Sep 1, 2026 | $19.12 | $19.46 | $18.62 | $18.92 | 561.08K |
| Aug 31, 2026 | $19.01 | $19.17 | $18.81 | $19.02 | 301.89K |
| Aug 28, 2026 | $19.38 | $19.61 | $19.14 | $19.21 | 361.13K |
| Aug 27, 2026 | $19.40 | $19.68 | $19.17 | $19.20 | 629.38K |
| Aug 26, 2026 | $19.50 | $19.95 | $19.24 | $19.43 | 601.11K |
| Aug 25, 2026 | $19.48 | $19.70 | $19.30 | $19.54 | 557.78K |
| Aug 24, 2026 | $20.00 | $20.30 | $19.42 | $19.47 | 699.83K |
| Aug 21, 2026 | $19.47 | $20.05 | $19.27 | $19.96 | 1.29M |
| Aug 20, 2026 | $19.66 | $19.745 | $19.105 | $19.48 | 518.04K |
| Aug 19, 2026 | $19.14 | $19.92 | $19.14 | $19.91 | 436.39K |
The latest Smart Investors Daily articles mentioning SIBN.
SIBN research
Company profile and research snapshot.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | TD Cowen | Buy | — |
| Aug 4, 2026 | UBS | Buy | — |
| Aug 4, 2026 | Truist Securities | Buy | — |
| Jul 28, 2026 | UBS | Buy | — |
| Jul 16, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
SI-BONE, Inc. (SIBN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 11:30 AM EDTCompany ParticipantsAnshul Maheshwari - COO...
Benzinga · Sep 11, 2026
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
Yahoo · Aug 31, 2026
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time. Investors interested i
Benzinga · Aug 4, 2026
UBS analyst Patrick Wood maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $25.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SIBN.
